Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 63

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs

Yuen, Kevin C. J., Miller, Bradley S., Boguszewski, Cesar L., Hoffman, Andrew R. · 2021 · Frontiers in Endocrinology

Abstract

Daily recombinant human GH (rhGH) is currently approved for use in children and adults with GH deficiency (GHD) in many countries with relatively few side-effects. Nevertheless, daily injections can be painful and distressing for some patients, often resulting in non-adherence and reduction of treatment outcomes. This has prompted the development of numerous long-acting GH (LAGH) analogs that allow for decreased injection frequency, ranging from weekly, bi-weekly to monthly. These LAGH analogs are attractive as they may theoretically offer increased patient acceptance, tolerability, and therapeutic flexibility. Conversely, there may also be pitfalls to these LAGH analogs, including an unphysiological GH profile and differing molecular structures that pose potential clinical issues in terms of dose initiation, therapeutic monitoring, incidence and duration of side-effects, and long-term safety. Furthermore, fluctuations of peak and trough serum GH and IGF-I levels and variations in therapeutic efficacy may depend on the technology used to prolong GH action. Previous studies of some LAGH analogs have demonstrated non-inferiority compared to daily rhGH in terms of increased growth velocity and improved body composition in children and adults with GHD, respectively, with no significant unanticipated adverse events. Currently, two LAGH analogs are marketed in Asia, one recently approved in the United States, another previously approved but not marketed in Europe, and several others proceeding through various stages of clinical development. Nevertheless, several practical questions still remain, including possible differences in dose initiation between naïve and switch-over patients, methodology of dose adjustment/s, timing of measuring serum IGF-I levels, safety, durability of efficacy and cost-effectiveness. Long-term surveillance of safety and efficacy of LAGH analogs are needed to answer these important questions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2021.637209

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 71

  1. Allen, 2016, Growth hormone safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults, Eur J Endocrinol, 174, 10.1530/EJE-15-0873 · DOI · Paper page
  2. Grimberg, 2016, Drug, Therapeutics C, Ethics Committee of the Pediatric Endocrine S. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency, Horm Res Paediatr, 86, 10.1159/000452150 · DOI · Paper page
  3. Richmond, 2016, Treatment of growth hormone deficiency in children, adolescents and at the transitional age, Best Pract Res Clin Endocrinol Metab, 30, 10.1016/j.beem.2016.11.005 · DOI
  4. Holdaway, 2015, Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults, Clin Endocrinol (Oxf), 83, 85, 10.1111/cen.12691 · DOI
  5. Kremidas, 2013, Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers, J Pediatr Nurs, 28, 55, 10.1016/j.pedn.2011.12.006 · doi:10.1016/j.pedn.2011.12.006
  6. Battelino, 2017, Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial, Clin Endocrinol (Oxf), 87, 10.1111/cen.13409 · DOI
  7. Chatelain, 2017, A randomized Phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency, J Clin Endocrinol Metab, 102, 10.1210/jc.2016-3776 · doi:10.1210/jc.2016-3776
  8. Cohen-Barak, 2017, Assessment of the pharmacokinetics, pharmacodynamics, and safety of single doses of TV-1106, a long-acting growth hormone, in healthy Japanese and Caucasian subjects, Clin Pharmacol Drug Dev, 6, 10.1002/cpdd.294 · DOI
  9. Cohen-Barak, 2015, Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency, Eur J Endocrinol, 173, 10.1530/EJE-15-0554 · DOI
  10. Fisher, 2017, Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children, Horm Res Paediatr, 87, 10.1159/000470842 · doi:10.1159/000470842
  11. Gilfoyle, 2018, A first-in-man phase 1 trial for long-acting TransCon Growth Hormone, Growth Horm IGF Res, 39, 10.1016/j.ghir.2017.12.002 · DOI
  12. Hou, 2016, Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children, Drug Des Devel Ther, 10, 13, 10.2147/DDDT.S93183 · DOI
  13. Hoybye, 2017, A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency, Endocr Connect, 6, 10.1530/EC-17-0007 · DOI
  14. Kramer, 2017, Pharmacokinetics, pharmacodynamics, and safety of a long-acting human growth hormone (MOD-4023) in healthy Japanese and Caucasian adults, Clin Pharmacol Drug Dev, 7, 10.1002/cpdd.414 · DOI
  15. Luo, 2017, Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies, Eur J Endocrinol, 177, 195, 10.1530/EJE-16-0905 · DOI
  16. Strasburger, 2017, MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults, Eur J Endocrinol, 176, 10.1530/EJE-16-0748 · DOI
  17. Thornton, 2019, TransCon growth hormone in the treatment of pediatric growth hormone deficiency: results of the Phase 3 heiGHt trial, J Endocrinol Soc, 3, 10.1210/js.2019-OR17-4 · DOI
  18. Hoffman, 2005, Genentech Adult Growth Hormone Deficiency Study G. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency, J Clin Endocrinol Metab, 90, 10.1210/jc.2005-0928 · DOI
  19. Kemp, 2004, Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children, J Clin Endocrinol Metab, 89, 10.1210/jc.2003-030825 · doi:10.1210/jc.2003-030825
  20. Silverman, 15, A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency, J Pediatr Endocrinol Metab 2002, 2, 10.1515/JPEM.2002.15.S2.715 · DOI
  21. Moore, 2016, A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency, J Clin Endocrinol Metab, 101, 10.1210/jc.2015-3279 · DOI
  22. Yuen, 2013, A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults, J Clin Endocrinol Metab, 98, 10.1210/jc.2013-1437 · DOI
  23. Laursen, 2001, Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults, J Clin Endocrinol Metab, 86, 10.1210/jc.86.3.1222 · DOI
  24. Burns, 1981, Final height and pubertal development in 55 children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with human growth hormone, Eur J Pediatr, 137, 10.1007/BF00441309 · DOI · Paper page
  25. Kastrup, 1983, Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children, Acta Endocrinol (Copenh), 104, 10.1530/acta.0.1040148 · doi:10.1530/acta.0.1040148
  26. Collett-Solberg, 2019, Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society international perspective, Horm Res Paediatr, 92, 1, 10.1159/000502231 · DOI · Paper page
  27. Jorgensen, 1989, Beneficial effects of growth hormone treatment in GH-deficient adults, Lancet, 1, 10.1016/S0140-6736(89)92328-3 · DOI · Paper page
  28. de Boer, 1996, Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers, J Clin Endocrinol Metab, 81, 10.1210/jcem.81.4.8636336 · DOI
  29. Johannsson, 1997, Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults, Clin Endocrinol (Oxf), 47, 10.1046/j.1365-2265.1997.3271123.x · DOI · Paper page
  30. Moller, 1993, Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters, Clin Endocrinol (Oxf), 39, 10.1111/j.1365-2265.1993.tb02386.x · DOI
  31. Cuneo, 1998, The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults, J Clin Endocrinol Metab, 83, 10.1210/jc.83.1.107 · DOI · Paper page
  32. Burman, 1997, Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women, J Clin Endocrinol Metab, 82, 10.1210/jc.82.2.550 · DOI · Paper page
  33. Johannsson, 1996, The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender, J Clin Endocrinol Metab, 81, 10.1210/jcem.81.4.8636370 · DOI · Paper page
  34. Christiansen, 2016, Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations, Eur J Endocrinol, 174, 10.1530/EJE-16-0111 · DOI
  35. Johnson, 1996, A month-long effect from a single injection of microencapsulated human growth hormone, Nat Med, 2, 10.1038/nm0796-795 · DOI · Paper page
  36. Peter, 2012, Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD), J Clin Endocrinol Metab, 97, 10.1210/jc.2011-2234 · DOI
  37. Hwang, 2018, Once-weekly administration of sustained-release growth hormone in Korean prepubertal children with idiopathic short stature: a randomized, controlled Phase II study, Horm Res Paediatr, 90, 54, 10.1159/000489262 · doi:10.1159/000489262
  38. de Schepper, 2011, Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics, Eur, 165, 10.1530/EJE-11-0536 · DOI
  39. Touraine, 2009, Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH, Eur J Endocrinol, 161, 10.1530/EJE-09-0422 · DOI
  40. Sprogoe, 2017, The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency, Endocr Connect, 6, 10.1530/EC-17-0203 · DOI
  41. Design and rationale for the height trial, a phase 3 transcon GH study in children with growth hormone deficiency BeckertM Brian KarpfD MortensenE MardellJ ChristoffersenED LeffJA Orlando, FLEndocrine Reviews. Conference: 99th Annual Meeting of the Endocrine Society, ENDO 2017. United States. Vol 382017
  42. Thygesen, 2017, Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone, Growth Horm IGF Res, 35, 8, 10.1016/j.ghir.2017.05.006 · doi:10.1016/j.ghir.2017.05.006
  43. Thygesen, 2016, (NNC0195-0092) a Novel Long Acting Human GH Derivative Binds Tightly, but Reversibly to Albumin in Plasma, i1
  44. Juul, 2019, Pharmacokinetics and pharmacodynamics of once-weekly Somapacitan in children and adults: supporting dosing rationales with a model-based analysis oftThree phase I trials, Clin Pharmacokinet, 58, 63, 10.1007/s40262-018-0662-5 · DOI
  45. Savendahl, 2020, Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial, J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa614 · doi:10.1210/clinem/dgaa614
  46. Johannsson, 2018, Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial, Eur J Endocrinol, 178, 10.1530/EJE-17-1073 · DOI
  47. Otsuka, 2020, Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone, Clin Endocrinol (Oxf), 93, 10.1111/cen.14273 · DOI
  48. Johannsson, 2020, Once-weekly Somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial, J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa049 · DOI
  49. Kim, 2017, Preclinical Pharmacokinetic and Pharmacodynamic Studies of a Novel, Long Acting Growth Hormone (AG-B1512), i1
  50. Lee, 2016, Human Phase 1 Clinical Data of ALT-P1 (hGH-NexP) by Healthy Korean Males, Horm Res Paediatr, 86, 1, 10.1159/000449142 · doi:10.1159/000449142
  51. Wilkinson, 2007, Ross RJ. A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist, Nat Med, 13, 10.1038/nm1610 · doi:10.1038/nm1610
  52. Kim, 2013, Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane, Nanoscale, 5, 10.1039/c3nr00474k · DOI
  53. Lee, 2018, A Pharmacokinetic-Pharmacodynamic Analysis Of GX-H9, A Long-acting Hybrid Fc-fused Recombinant Human Growth Hormone (rhGH), i1
  54. Ku, 2018, Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults, Eur J Endocrinol, 179, 10.1530/EJE-18-0185 · DOI
  55. Kang, 2015, A Novel Long Acting Growth Hormone (HM10560A) Demonstrated Good Tolerability and Weekly Potential in Healthy Male Subjects after Single Administration, i1
  56. Kang, 2015, 6 Month Results of a Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long Acting r-Hgh-HMC001 Conjugate in Adult Patients with Growth Hormone Deficiency (AGHD), i1
  57. Zelinska, 2017, Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children, J Clin Endocrinol Metab, 102, 10.1210/jc.2016-3547 · DOI
  58. Miller, 2020, Long-acting growth hormone preparations - current status and future considerations, J Clin Endocrinol Metab, 105, dgz149, 10.1210/clinem/dgz149 · DOI
  59. Lippe, 1979, Use of growth hormone-gel, Arch Dis Child, 54, 10.1136/adc.54.8.609 · doi:10.1136/adc.54.8.609
  60. Biller, 2013, Twelve-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency, Pituitary, 16, 10.1007/s11102-012-0422-8 · doi:10.1007/s11102-012-0422-8
  61. Hoybye, 2015, Status of long-acting-growth hormone preparations–2015, Growth Horm IGF Res, 25, 10.1016/j.ghir.2015.07.004 · DOI
  62. Boguszewski, 2017, Update on GH therapy in adults, F1000Res, 6, 2017, 10.12688/f1000research.12057.1 · DOI
  63. Maniatis, 2020, Phase 3 fliGHt trial: experience of switching from daily growth hormone therapy to once-weekly TransCon HGH in children with growth hormone deficiency, J Endocrinol Soc, 4, 10.1210/jendso/bvaa046.963 · doi:10.1210/jendso/bvaa046.963
  64. Deal, 2020, Somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric Phase 3 clinical trial, J Endocrinol Soc, 4, 10.1210/jendso/bvaa046.1279 · doi:10.1210/jendso/bvaa046.1279
  65. Rasmussen, 2014, A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile, J Clin Endocrinol Metab, 99, 10.1210/jc.2014-1702 · DOI
  66. Rasmussen, 2016, Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency, J Clin Endocrinol Metab, 101, 10.1210/jc.2015-1991 · DOI
  67. Boguszewski, 2020, Individual sensitivity to growth hormone replacement in adults, Rev Endocr Metab Disord, 10.1007/s11154-020-09605-1 · DOI
  68. Ahangari, 2004, Growth hormone antibodies formation in patients treated with recombinant human growth hormone, Int J Immunopathol Pharmacol, 17, 10.1177/039463200401700105 · DOI
  69. Binder, 2019, Biological Significance of Anti-GH Antibodies in Children Treated with rhGH, Horm Res Paediatr, 91, 17, 10.1159/000497409 · doi:10.1159/000497409
  70. Hoybye, 2013, Long-acting growth hormone, Paediatr Drugs, 15, 10.1007/s40272-013-0059-8 · DOI
  71. Johannsson, 2011, Long-acting growth hormone for replacement therapy, J Clin Endocrinol Metab, 96, 10.1210/jc.2011-0689 · DOI

Cited by

See all 63

Metadata

Authors
Yuen, K. C. J., Miller, B. S., Boguszewski, C. L., & Hoffman, A. R.
Venue
Frontiers in Endocrinology
Published
2021-02-24
Volume
12
ISSN
1664-2392
Cited by
63
References
7

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. https://app.cochat.ai/papers/10.3389/fendo.2021.637209
The paper
Yuen, K. C. J., Miller, B. S., Boguszewski, C. L., & Hoffman, A. R. (2021). Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.637209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.